Digital health VC reaches $4 billion in Q1 2026, up $1B year-over-year

The $4B Q1 figure is significant because digital health investment had been in a meaningful correction from the 2021 peak — characterized by massive rounds for companies with thin clinical evidence and unclear paths to reimbursement. The 2022–2024 period was marked by down-rounds, layoffs, and contraction. A return to $4B/quarter suggests investor appetite has recovered, but the mix has changed.

The 2021 peak was driven partly by pandemic-era telehealth enthusiasm and partly by low-interest-rate-era risk-on investing. The 2026 recovery appears to be more focused: chronic disease management (GLP-1-adjacent cardiometabolic platforms, diabetes technology), AI infrastructure for health systems (rather than direct-to-consumer), and clinical workforce tools. These are categories with clearer reimbursement pathways, demonstrated enterprise buyers, and — at least in some cases — more rigorous evidence standards than the 2021 cohort.

UnitedHealth projecting $1 billion in AI cost savings and HCA Healthcare projecting $400 million are signal events for investor confidence. When the largest health systems publicly commit to AI savings at that scale, it validates that there are enterprise buyers willing to pay for the category. That validation reduces perceived market risk for investors.

The workforce technology segment deserves attention separately. Chronic clinician shortages — particularly in nursing, primary care, and behavioral health — are creating demand for AI tools that extend existing clinicians’ capacity, and that category is attracting capital that would have gone into direct care-delivery startups in an earlier cycle.